title: The effects of ibuprofen on sepsis parameters in preterm neonates.
abstract: OBJECTIVE
  To examine the effects of ibuprofen used for patent ductus arteriosus (PDA) treatment on the production of the proinflammatory cytokines C-reactive protein (CRP) and interleukin 6 (IL-6) in preterm septic newborns.
  
  
  METHODS
  Patients with acute phase reactant elevation were divided into two groups according to receiving ibuprofen (Group I, n=51) or not (Group II, n=38). Course of sepsis was evaluated by CRP and IL-6 levels.
  
  
  RESULTS
  CRP and IL-6 levels at the time of diagnosis were not different between two groups [16±9.1 vs 16.4±13.2mg/dL (p=0.43) for CRP and 124±82 vs 119±73mg/dL (p=0.517) for IL-6, respectively]. Similarly, they were statistically insignificant between the groups at the 2nd or 3rd days of ibuprofen treatment [14.3±7.7 vs 13.7±5.9mg/dL (p=0.21) for CRP and 83±46 vs 86±37mg/dL (p=0.29) for IL-6, respectively]. However, CRP and IL6 levels showed significant difference between groups in the following days; 6.03±3.8 vs 9.1±4.9mg/dL (p=0.025) for CRP and 42±33.1 vs 58.9±27.1mg/dL (0.011) for IL-6 on 4th or 5th days of treatment and 2.3±3.2 vs 4.1±2.3mg/dL (p=0.032) for CRP and 16.1±12.4 vs 21.3±16.8mg/dL (p=0.016) for IL-6, on 7th to 10th days of treatment, respectively.
  
  
  CONCLUSIONS
  IL-6 and CRP may decrease in infants receiving ibuprofen treatment more than infants who do not receive it. This decrease should be considered at the time of caring a preterm infant with both sepsis and PDA after ibuprofen treatment.
authors.affiliation: Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey. kgamze@hotmail.com
authors.forename: Gamze
authors.initials: G
authors.lastname: Demirel
authors.forename: Istemi Han
authors.initials: IH
authors.lastname: Celik
authors.forename: Fuat Emre
authors.initials: FE
authors.lastname: Canpolat
authors.forename: Omer
authors.initials: O
authors.lastname: Erdeve
authors.forename: Serife Suna
authors.initials: SS
authors.lastname: Oguz
authors.forename: Ugur
authors.initials: U
authors.lastname: Dilmen
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D004374:Ductus Arteriosus, Patent / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005865:Gestational Age; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology* / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood / Q000276:immunology / Q000502:physiology; D007235:Infant, Premature, Diseases / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D015850:Interleukin-6 / Q000032:analysis / Q000097:blood; D018805:Sepsis / Q000097:blood / Q000151:congenital / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D015850:Interleukin-6; D002097:C-Reactive Protein; D007052:Ibuprofen